Fundraising FoxEleven Biotherapeutics
Cambridge, US · Delaware corporation · 1 known investors
Find your way into Eleven Biotherapeutics
Sign up to find every way you can get introduced to Eleven Biotherapeutics
- Your email: who you already know at Eleven Biotherapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Eleven Biotherapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
DA
David A. BerryFounder
SH
Stephen HurlyExecutive
AP
Arthur P. DeCillisExecutive
GD
Gregory D. PerryExecutive
ES
Eric S. FurfineExecutive
KL
Karen L. TurbridyExecutive
Board
DS
Daniel S. LynchBoard director
AC
Abbie C. Celniker, Ph.D.Board director
CG
PG
Paul G. ChaneyBoard director
JS
Jay S. DukerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$34.5M disclosed across 3 rounds · 2014–2018
▶$996KraisedApr 2018 · 10 investors · BiotechnologyRule 506(b)
▶$996KraisedApr 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barry J. GertzDirector
- Richard F. FitzgeraldExecutive Officer
- Leslie DanDirector
- Jane V. HendersonDirector
- Wendy L. DixonDirector
- Paul G. ChaneyDirector
- Stephen A. HurlyExecutive Officer, Director
- Abbie C. CelnikerDirector
- Jay S. DukerDirector
- Daniel S. LynchDirector
- Offering amount
- $996K
- Amount sold
- $996K
- Sales commissions
- $36.1K
- Finders' fees
- $30.9K
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.5MraisedSep 2016 · 6 investors · BiotechnologyRule 506(b)
▶$13.5MraisedSep 2016 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel S. LynchDirector
- Paul G. ChaneyDirector
- Stephen HurlyExecutive Officer, Director
- John McCabeExecutive Officer
- Jay S. DukerDirector
- Wendy L. DixonDirector
- Barry J. GertzDirector
- Abbie C. Celniker, Ph.D.Director
- Leslie DanDirector
- Jane V. HendersonDirector
- Arthur P. DeCillisExecutive Officer
- Offering amount
- $13.5M
- Amount sold
- $13.5M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedDec 2014 · 10 investors · BiotechnologyRule 506(b)
▶$20MraisedDec 2014 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David A. BerryExecutive Officer, Director
- Gregory D. PerryExecutive Officer
- Daniel S. LynchDirector
- Eric S. FurfineExecutive Officer
- Abbie C. Celniker, Ph.D.Executive Officer, Director
- Paul ChaneyDirector
- Jane V. HendersonDirector
- Karen L. TurbridyExecutive Officer
- Cary G. PfefferDirector
- Wendy L. DixonDirector
- Offering amount
- $20M
- Amount sold
- $20M
- Sales commissions
- $1.4M
- Placement agents
- Cowen and Company, LLC, Leerink Partners LLC, Citigroup Global Markets Inc.
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Eleven Biotherapeutics went on to found or lead other companies.
Frequently asked questions
- Who founded Eleven Biotherapeutics?
- Eleven Biotherapeutics was founded by David A. Berry.
- Who are Eleven Biotherapeutics's investors?
- Eleven Biotherapeutics's investors include Third Rock Ventures.
- How much funding has Eleven Biotherapeutics raised?
- Eleven Biotherapeutics has disclosed $34.5M raised across 3 rounds.
- Where is Eleven Biotherapeutics headquartered?
- Eleven Biotherapeutics is headquartered in Cambridge, US.